BIOCLONAL
Información de contacto
- Biofármacos
- Biomarcadores
- Drug discovery
- Enfermedades inflamatorias
- Inmunología
- Oftalmología y optometría
- Oncología
- Sistema nervioso central
- Empresas CRO / CMO / SMO
BioClonal specializes in overcoming the technical barriers of anti-peptide antibody development. We provide custom services that empower the diagnostic and therapeutic industries, delivering high-specificity binders for in vitro diagnostic (IVD) assays, production controls, and drug monitoring in serum, including anti-drug antibody (ADA) detection.
Our expertise addresses the challenge of low immunogenicity, transforming complex peptide targets into precision tools. We offer end-to-end support, covering every stage from advanced immunogen design and in vivo immunization to antibody validation and production. Whether the need is for a specific binder for a clinical kit, a control for therapeutic validation, or a research reagent, BioClonal delivers validated sequences tailored to each project’s success.
Through our proprietary pipeline, we are developing monoclonal antibodies targeting key biomarkers for diabetes (insulin, proinsulin, C-peptide) and Alzheimer’s disease (Aβ 1–16 and derived peptides), combining diagnostic and therapeutic applications. We are committed to collaborating with biotech companies, pharmaceutical developers, and research institutions to co-develop solutions that accelerate innovation, improve patient care, and advance the next generation of peptide-targeted antibody technologies.
BioClonal offers a comprehensive portfolio of services and proprietary antibody programs, focused on anti-peptide monoclonal antibodies for diagnostics, therapeutics, and biomolecule monitoring.
Custom Services
-
Design and development of high-specificity monoclonal antibodies for IVD assays, production controls, and drug monitoring, including anti-drug antibody detection.
-
End-to-end expertise covering advanced immunogen design, in vivo immunization, antibody validation, and production.
-
Tailored solutions for clinical kits, therapeutic validation, or research reagents, with validated sequences optimized for each project.
Proprietary Pipeline
-
Diabetes Biomarker Antibody Program (Insulin, Proinsulin & C-Peptide): Monoclonal antibodies for ultrasensitive detection of key diabetes biomarkers in diagnostic assays.
-
Alzheimer’s Disease Aβ Biomarker Antibody Program (Aβ 1–16): Monoclonal antibodies for early detection and biomarker research in Alzheimer’s disease.
-
Alzheimer’s Disease Aβ-Derived Biomarker Antibody Program: Next-in-series antibodies targeting derived Aβ peptides, with dual potential for diagnostics and therapeutic intervention.
By combining custom services with a strong proprietary pipeline, BioClonal enables partners to accelerate innovation, develop next-generation diagnostics, and explore novel therapeutic strategies using peptide-targeted antibodies.
|
We partner with organizations on diagnostic and therapeutic projects, providing tailored anti-peptide antibodies. Our solutions enable high-specificity biomolecules for research, assays, and therapeutic development. |
Biotech Sanitaria
| Producto / Servicio | Tipo | Área terapéutica | Aplicación | Fase de desarrollo |
|---|---|---|---|---|
| Amyloid-Beta–derived biomarker antibody program | Biomarkers, Diagnostic | Sistema nervioso central | Intended for use as in vitro diagnostic and research reagents, and as investigational therapeutic antibodies. Applications include integration into ultrasensitive immunoassays for biomarker detection and quantification, clinical and translational research, assay development and validation, and as potential therapeutic agents to modulate circulating levels of the derived amyloid-beta peptide in patients. This program represents the next step in expanding our Alzheimer’s disease peptide-targeted antibody portfolio. | R&D |
| Amyloid-Beta biomarker antibody program (Aβ 1–16) | Diagnostic | Sistema nervioso central | Intended for use as in vitro diagnostic and research reagents, including integration into ultrasensitive immunoassays for detection and quantification of Aβ 1–16. Applications include clinical and translational research, biomarker studies, assay development and validation, and use as analytical or reference reagents for monitoring Alzheimer’s disease–related peptides in biological samples. | R&D |
| Peptide-based diagnostic antibodies for Diabetes | Diagnostic | Trastornos metabólicos / Endocrinología | Intended for use as in vitro diagnostic reagents in diabetes testing, with application in ultrasensitive immunoassays for biomarker quantification. Use cases include integration into diagnostic platforms, assay development and validation, clinical research, and use as analytical or reference reagents for monitoring insulin, proinsulin and C-peptide levels in biological samples. | R&D |